EME. A. Mamedov

E. A. Mamedov

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


E. A. Mamedov has a total of 8 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Packed red blood cell transfusions in perioperative period in patients with gastrointestinal malignancies

    by A.V. Sazhin, I.B. Kumukova, I.V. Ermakov, K.D. Dalgatov, E.A. Mamedov

    Objective. To compare the incidence of postoperative complications in patients with gastrointestinal cancer and anemia depending on red blood cell transfusion. Material and methods. We analyzed treatment outcomes in patients with anemia who underwent surgery between 01.01.2022 and 30.01.2024. The main group included 105 patients who received red blood cell transfusions, the control group — 124 patients without transfusions. We assessed postoperative complications according to the Clavien-Dindo classification, length of hospital stay, readmission, 30-day and 90-day mortality. Results. The study included 229 patients. Transfusions were performed in 105 (45.9%) patients, and there were no transfusions in 124 (54.1%) patients. Postoperative complications were more common in patients with transfusions (26.6% vs. 45.7%, p=0.003) (mainly Clavien-Dindo grade II (15.3% vs. 36.2%, p<0.001) and grade V (0% vs. 7.6%, p=0.002)). In patients with transfusions, hospital stay was 14 days, without transfusion — 11 days (p=0.001). Readmission rate (0% versus 14.3%, p<0.001), 30-day (0% and 6.7%, p=0.004) and 90-day mortality (0% and 11.4%, p<0.001) were higher in the transfusion group. Conclusion. Correction of anemia with red blood cell transfusions in patients with gastrointestinal cancer increases the incidence of postoperative complications, length of hospital stay, readmission rate, 30-day and 90-day mortality.

  • Open Access

    Assessment of transfusion requirements of allogeneic haematopoietic stem cell transplantation recipients and factors influencing it

    by I. B. Kumukova, N. N. Starostin, E. A. Mamedov, A. V. Protsvetkina, D. N. Balashov, P. E. Trakhtman

    Introduction. Allogeneic haematopoietic stem cell transplantation (HSCT) is actively used in clinical practice for the treatment of various diseases. Recipients of allogeneic HSCT require significant amounts of transfusion therapy, but the real need for transfusions and factors influencing this need have not been assessed in domestic practice. Materials and methods . A retrospective analysis of the need for transfusions of blood components of recipients of the first allogeneic HSCT performed in 2018–2022 during the observation period of 1 year was performed. The volumes of transfusions performed were calculated for each type of blood components. The transfusion-dependent period is represented by the number of days until the transfusion independence criteria were reached. The incidence of loss of transfusion independence is presented. The influence of various factors on transfusion requirement and transfusion independence was assessed. Results and discussion . The median number of red blood cells transfusions was 2 (IQR 1–4), the median number of platelet transfusions was 5 (IQR 3–10). The only factor that influenced the volume of transfusion therapy was the type of diagnosis more transfusions were required for nonmalignant diseases. The duration of the transfusion-dependent period was influenced by the type of diagnosis, haematopoietic stem cell source and donor type. Gender differences between donor and recipient, as well as differences in ABO and conditioning regime did not influence either transfusion requirement or independence from transfusions. Conclusion. This analysis presents the need for transfusions of donor blood components in allogeneic HSCT recipients during 1 year. The results of the analysis can be used for planning the activities of transplantation centres and blood service institutions to provide transfusion support for HSCT recipients.

  • Open Access

    Transfusions of pathogen-reduced components of donor blood to recipients of allogeneic hematopoietic stem cell transplantation

    by I. B. Kumukova, N. N. Starostin, E. A. Mamedov, P. E. Trakhtman

    Introduction. Pathogen reduction technologies (PRT) in donor blood components have become a new milestone in ensuring the safety of transfusions. However, it is widely acknowledged that the use of PRT can compromise the quality of blood components and potentially diminish the efficiency of transfusion.The purpose of this retrospective analysis is the presentation of the results of the use of pathogenic-reduced components of donor blood in comparison with standard transfusion practice in hematopoietic stem cell transplantation (HSCT) recipients.Materials and methods. An analysis was conducted of the results of transfusions to recipients of allogeneic HSCT performed in 2018–2022. We presented results of 1901 red blood cell transfusions (1848 of which were gamma-irradiated and 53 were pathogen-reduced), 8192 platelet concentrates transfusions (7654 of which were gamma-irradiated and 538 were pathogen-reduced) and donor plasma transfusions (freshly frozen plasma (FFP) – 1381, pathogen-reduced – 169).Results. The estimated laboratory efficiency of the transfusion of pathogen-reduced red blood cells was comparable to that of gamma-irradiated. Platelet concentrates subjected to pathogen reduction, as well as those prepared using an additional solution, demonstrated the lowest results of post-transfusion increase compared to gamma-irradiated platelet concentrates. Plasma processed using the pathogen reduction method resulted in a smaller increase in fibrinogen concentration. All other hemostasis indices were comparable to those of FFP.Conclusion. The clinical use of pathogen-reduced donor blood components is an effective transfusion practice, but further improvements in TRP are needed.